Icon
+91 94997 68112
Login Register

Trilipix - (135mg, 45mg; Capsule Delayed release oral)

Fenofibrate Choline Abbvie
135mg, 45mg; Capsule Delayed release oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
More Than 5
More Than 5
Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: • Reduce TG in patients with severe hypertriglyceridemia. • Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia
Yes
***** *** *** ***** ** **** **** ** **** ****** ******* ******** ** * *** ****. ******* ******, *****, ***** *** ******* ***** ****** *********** ****** '*** *** **** ************ *********. ****** ** ****** **** ****** ****** & ***** ******* * ********** ********* ** ***** ***** *** ****** *** ******* ** ***. *, **** ** ** ***** ** **** **, **** ***** ******* *************. ***** ********** *** ******* **** ****** (*******), ***** *** ***** ** ****, ***** *** ********* ******** *** ******* ****** *** ****** ***** *****. ***** ******** *** ******* ** ********** *******. ******* *** ** ****** *** **** *** ******** ** *** **** ****** ******** *******. ***** ** ******** ******** **% ** **** *** ** ******* ***** *** ****** *** ********. ***** ****** *** ********* *** *** **** ** **** ****** '***, ******* *** ********** *** ********* ***** *** ***** ** ********* *** *** ***** *** ****** *** *** ******** *** ******* ***. ***** ** ** ******* ** ****** '*** *** ** ** ***** ***** ** *** ****** **** ** *** ********* ***** ******** *** *** **** ** ******. **** ** * ******* *********** ******* ***** ** *** **********.
  1. ***, **** : ***** ******** ****** ***** *** **** ** *** **** & ***** ********, ** ****** '***.
  2. ***, **** : ***** ******** ****** ***** *** **** ** *** ** *** ***** ******** ** ****** ***'.
  3. ***, **** : ****** ***** **** ******* ***** ** ******** ***** ** **.
  4. ***, **** : ****** ******** ****** ***** *** **** ** *** ** *** ***** ******** ** ****** ***'.
  5. *****, **** : ***** **** ****** ** ******** ***** ** *** ******.
  6. ***, **** : ****** **** ***** ** ******** ***** ** **
  7. *****, **** : ****** **** ***** *** ****** (** ******** ***** ** ********* *******).
  8. *****, **** : ******* ******** ****** ***** ****** ** *** **** *** ** *** ***** *** ****** *** ** ******** ***** ** **.
  9. *****, **** : ****** **** *******.
  10. *** **, **** : ****** & ***** ******* * ********** ********* ** ***** ***** *** ****** *** ******* ** ***. *, **** ** ** ***** ** **** **, **** ***** ******** *************.
  11. *** **, **** : *** *** ********** ** *** **** ********* *** **** ***** * ***** *** ******* ********* ** ********** *** ***-************ ** ****** '***.
  12. *** **, **** : ********** ****** *** ******* ********* *** ******.
  13. **** **, **** : ****** **** ******* **** ******, ***** *** *****.
  14. *** **, **** : ***** ***** * **** ******* ****** ** ****** ***** **** ** **** ****** '***.
  15. *** **, **** : ********** *** ********* **** ****** ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.